

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 723 013 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
18.06.2003 Bulletin 2003/25

(51) Int Cl.7: **C12N 15/12, C07K 14/51,
C07K 16/22, A61K 38/18,
A61L 27/00, C12N 1/21**

(21) Application number: **96200044.4**

(22) Date of filing: **07.04.1989**

(54) **Biosynthetic osteogenic proteins and osteogenic devices containing them**

Biosynthetische knochenbildende Proteine, und sie enthaltende knochenbildende Vorrichtungen

Protéines biosynthétiques ostéogènes, et dispositifs contenant les-dites

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: **08.04.1988 US 179406
15.08.1988 US 232630
23.02.1989 US 315342**

(43) Date of publication of application:
24.07.1996 Bulletin 1996/30

(60) Divisional application:
01201555.8 / 1 221 484

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
89904959.7 / 0 372 031

(73) Proprietor: **STRYKER CORPORATION**
Kalamazoo, Michigan 49003-4085 (US)

(72) Inventors:
• **Opperman, Hermann**
Medway, Massachusetts 02053 (US)
• **Kuberasampath, Thangavel**
Medway, Massachusetts 02053 (US)

• **Rueger, David C.**
West Roxbury, Massachusetts 02132 (US)

(74) Representative: **Price, Vincent Andrew et al**
Fry Heath & Spence LLP
The Gables
Massetts Road
Horley Surrey RH6 7DQ (GB)

(56) References cited:
EP-A- 0 169 016 WO-A-88/00205
WO-A-90/11366

- **PADGETT, R.W. ET AL.:** "A transcript from drosophila pattern gene predicts a protein homologous to the transforming growth factor-beta family" **NATURE**, vol. 325, 1987, page 81-84 XP002036812
- **ÖZKAYNAK, E. ET AL.:** "OP-1 cDNA encodes an osteogenic protein in the TGF-beta family" **EMBO J.**, vol. 9, no. 7, 1990, page 2085-2093 XP000611252
- **CELESTE, A.J ET AL.:** "Identification of transforming growth factor beta family members ..." **PROC. NATL. ACAD. SCI. USA**, vol. 87, no. 24, 1990, pages 9843-9847, XP000168624

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 723 013 B1

Description

[0001] This invention relates to osteogenic devices, to synthetic genes encoding proteins which can induce osteogenesis in mammals and methods for their production using recombinant DNA techniques, to synthetic forms of osteogenic protein, and to bone and cartilage repair procedures using osteogenic device comprising the synthetic proteins.

[0002] Mammalian bone tissue is known to contain one or more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

[0003] The developmental cascade of bone differentiation consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

[0004] Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone differentiation activity of bone matrix can be dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This provides an experimental method for assaying protein extracts for their ability to induce endochondral bone in vivo.

[0005] This putative bone inductive protein has been shown to have a molecular mass of less than 50 kilodaltons (kD). Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595).

[0006] The potential utility of these proteins has been widely recognized. It is contemplated that the availability of the pure protein would revolutionize orthopedic medicine, certain types of plastic surgery, and various periodontal and craniofacial reconstructive procedures.

[0007] The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from mammalian bone is disclosed by Sampath et al. (Proc. Natl. Acad. Sci. USA (1987) 80). Urist et al. (Proc. Soc. Exp. Biol. Med. (1984) 173:194-199) disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

[0008] Urist et al. (Proc. Natl. Acad. Sci. USA (1984) 81:371-375) disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract from bone results in ill-defined and impure preparations.

[0009] European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into animals.

[0010] International Application No. PCT/087/01537, published January 14, 1988, discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative bone inductive factors produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and apparently expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic proteins, bone induction was not demonstrated. See also Urist et al., EP 0,212,474 entitled Bone Morphogenic Agents.

[0011] Wang et al. (Proc. Nat. Acad. Sci. USA (1988) 85: 9484-9488) discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been determined.

[0012] Wozney et al. (Science (1988) 242: 1528-1534) discloses the isolation of full-length cDNA's encoding the human equivalents of three polypeptides originally purified from bovine bone. The authors report that each of the three recombinantly expressed human proteins are independently or in combination capable of inducing cartilage formation. No evidence of bone formation is reported.

[0013] It is an object of this invention to provide osteogenic devices comprising matrices containing dispersed osteogenic protein capable of bone induction in allogenic and xenogenic implants. Another object is to provide synthetic osteogenic proteins capable of inducing endochondral bone formation in mammals, including humans. Yet another

object is to provide genes encoding non-native osteogenic proteins and methods for their production using recombinant DNA techniques. Another object is to provide novel biosynthetic forms of osteogenic proteins and a structural design for novel, functional osteogenic proteins. Another object is to provide methods for inducing cartilage formation.

[0014] These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

Summary of the Invention

[0015] This invention involves osteogenic devices which, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation and bone marrow differentiation. Suitably modified as disclosed herein, the devices also may be used to induce cartilage formation. The devices comprise a carrier material, referred to herein as a matrix, having the characteristics disclosed below, containing dispersed osteogenic protein in the form of a biosynthetic construct.

[0016] Key to these developments was the successful preparation of substantially pure osteogenic protein by purification from bone, the elucidation of amino acid sequence and structure data of the native osteogenic protein, and insights involving study of the DNA and amino acid sequences of the natural source product. A protocol was developed which results in retrieval of active, substantially pure osteogenic protein from mammalian bone. Investigation of the properties and structure of the native form osteogenic protein then permitted the inventors to develop a rational design for non-native forms, i.e., forms never before known in nature, capable of inducing bone formation. As far as applicants are aware, the constructs disclosed herein constitute the first instance of the design of a functional, active protein without preexisting knowledge of the active region of a native form nucleotide or amino acid sequence.

[0017] A series of consensus DNA sequences were designed with the goal of producing an active osteogenic protein. The sequences were based on partial amino acid sequence data obtained from the naturally sourced product and on observed homologies with unrelated genes reported in the literature, or the sequences they encode, having a presumed or demonstrated developmental function. Several of the biosynthetic consensus sequences have been expressed as fusion proteins in procaryotes, purified, cleaved, refolded, combined with a matrix, implanted in an established animal model, and shown to have endochondral bone-inducing activity. The currently preferred active proteins comprise sequences designated COPS, COP7, COP16, and OP1. The amino acid sequences of these proteins are set forth below.

```

1      10      20      30      40
COP5  LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPFPLAD
      50      60      70
      HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
      80      90     100
      ISMLYLDENEKVVVLKNYQEMVVEGCGCR

```

```

1      10      20      30      40
COP7  LYVDFS-DVGWDDWIVAPPGYHAFYCHGECPFPLAD
      50      60      70
      HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
      80      90     100
      ISMLYLDENEKVVVLKNYQEMVVEGCGCR

```

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995
 1000
 1005
 1010
 1015
 1020
 1025
 1030
 1035
 1040
 1045
 1050
 1055
 1060
 1065
 1070
 1075
 1080
 1085
 1090
 1095
 1100
 1105
 1110
 1115
 1120
 1125
 1130
 1135
 1140
 1145
 1150
 1155
 1160
 1165
 1170
 1175
 1180
 1185
 1190
 1195
 1200
 1205
 1210
 1215
 1220
 1225
 1230
 1235
 1240
 1245
 1250
 1255
 1260
 1265
 1270
 1275
 1280
 1285
 1290
 1295
 1300
 1305
 1310
 1315
 1320
 1325
 1330
 1335
 1340
 1345
 1350
 1355
 1360
 1365
 1370
 1375
 1380
 1385
 1390
 1395
 1400
 1405
 1410
 1415
 1420
 1425
 1430
 1435
 1440
 1445
 1450
 1455
 1460
 1465
 1470
 1475
 1480
 1485
 1490
 1495
 1500
 1505
 1510
 1515
 1520
 1525
 1530
 1535
 1540
 1545
 1550
 1555
 1560
 1565
 1570
 1575
 1580
 1585
 1590
 1595
 1600
 1605
 1610
 1615
 1620
 1625
 1630
 1635
 1640
 1645
 1650
 1655
 1660
 1665
 1670
 1675
 1680
 1685
 1690
 1695
 1700
 1705
 1710
 1715
 1720
 1725
 1730
 1735
 1740
 1745
 1750
 1755
 1760
 1765
 1770
 1775
 1780
 1785
 1790
 1795
 1800
 1805
 1810
 1815
 1820
 1825
 1830
 1835
 1840
 1845
 1850
 1855
 1860
 1865
 1870
 1875
 1880
 1885
 1890
 1895
 1900
 1905
 1910
 1915
 1920
 1925
 1930
 1935
 1940
 1945
 1950
 1955
 1960
 1965
 1970
 1975
 1980
 1985
 1990
 1995
 2000
 2005
 2010
 2015
 2020
 2025
 2030
 2035
 2040
 2045
 2050
 2055
 2060
 2065
 2070
 2075
 2080
 2085
 2090
 2095
 2100
 2105
 2110
 2115
 2120
 2125
 2130
 2135
 2140
 2145
 2150
 2155
 2160
 2165
 2170
 2175
 2180
 2185
 2190
 2195
 2200
 2205
 2210
 2215
 2220
 2225
 2230
 2235
 2240
 2245
 2250
 2255
 2260
 2265
 2270
 2275
 2280
 2285
 2290
 2295
 2300
 2305
 2310
 2315
 2320
 2325
 2330
 2335
 2340
 2345
 2350
 2355
 2360
 2365
 2370
 2375
 2380
 2385
 2390
 2395
 2400
 2405
 2410
 2415
 2420
 2425
 2430
 2435
 2440
 2445
 2450
 2455
 2460
 2465
 2470
 2475
 2480
 2485
 2490
 2495
 2500
 2505
 2510
 2515
 2520
 2525
 2530
 2535
 2540
 2545
 2550
 2555
 2560
 2565
 2570
 2575
 2580
 2585
 2590
 2595
 2600
 2605
 2610
 2615
 2620
 2625
 2630
 2635
 2640
 2645
 2650
 2655
 2660
 2665
 2670
 2675
 2680
 2685
 2690
 2695
 2700
 2705
 2710
 2715
 2720
 2725
 2730
 2735
 2740
 2745
 2750
 2755
 2760
 2765
 2770
 2775
 2780
 2785
 2790
 2795
 2800
 2805
 2810
 2815
 2820
 2825
 2830
 2835
 2840
 2845
 2850
 2855
 2860
 2865
 2870
 2875
 2880
 2885
 2890
 2895
 2900
 2905
 2910
 2915
 2920
 2925
 2930
 2935
 2940
 2945
 2950
 2955
 2960
 2965
 2970
 2975
 2980
 2985
 2990
 2995
 3000
 3005
 3010
 3015
 3020
 3025
 3030
 3035
 3040
 3045
 3050
 3055
 3060
 3065
 3070
 3075
 3080
 3085
 3090
 3095
 3100
 3105
 3110
 3115
 3120
 3125
 3130
 3135
 3140
 3145
 3150
 3155
 3160
 3165
 3170
 3175
 3180
 3185
 3190
 3195
 3200
 3205
 3210
 3215
 3220
 3225
 3230
 3235
 3240
 3245
 3250
 3255
 3260
 3265
 3270
 3275
 3280
 3285
 3290
 3295
 3300
 3305
 3310
 3315
 3320
 3325
 3330
 3335
 3340
 3345
 3350
 3355
 3360
 3365
 3370
 3375
 3380
 3385
 3390
 3395
 3400
 3405
 3410
 3415
 3420
 3425
 3430
 3435
 3440
 3445
 3450
 3455
 3460
 3465
 3470
 3475
 3480
 3485
 3490
 3495
 3500
 3505
 3510
 3515
 3520
 3525
 3530
 3535
 3540
 3545
 3550
 3555
 3560
 3565
 3570
 3575
 3580
 3585
 3590
 3595
 3600
 3605
 3610
 3615
 3620
 3625
 3630
 3635
 3640
 3645
 3650
 3655
 3660
 3665
 3670
 3675
 3680
 3685
 3690
 3695
 3700
 3705
 3710
 3715
 3720
 3725
 3730
 3735
 3740
 3745
 3750
 3755
 3760
 3765
 3770
 3775
 3780
 3785
 3790
 3795
 3800
 3805
 3810
 3815
 3820
 3825
 3830
 3835
 3840
 3845
 3850
 3855
 3860
 3865
 3870
 3875
 3880
 3885
 3890
 3895
 3900
 3905
 3910
 3915
 3920
 3925
 3930
 3935
 3940
 3945
 3950
 3955
 3960
 3965
 3970
 3975
 3980
 3985
 3990
 3995
 4000
 4005
 4010
 4015
 4020
 4025
 4030
 4035
 4040
 4045
 4050
 4055
 4060
 4065
 4070
 4075
 4080
 4085
 4090
 4095
 4100
 4105
 4110
 4115
 4120
 4125
 4130
 4135
 4140
 4145
 4150
 4155
 4160
 4165
 4170
 4175
 4180
 4185
 4190
 4195
 4200
 4205
 4210
 4215
 4220
 4225
 4230
 4235
 4240
 4245
 4250
 4255
 4260
 4265
 4270
 4275
 4280
 4285
 4290
 4295
 4300
 4305
 4310
 4315
 4320
 4325
 4330
 4335
 4340
 4345
 4350
 4355
 4360
 4365
 4370
 4375
 4380
 4385
 4390
 4395
 4400
 4405
 4410
 4415
 4420
 4425
 4430
 4435
 4440
 4445
 4450
 4455
 4460
 4465
 4470
 4475
 4480
 4485
 4490
 4495
 4500
 4505
 4510
 4515
 4520
 4525
 4530
 4535
 4540
 4545
 4550
 4555
 4560
 4565
 4570
 4575
 4580
 4585
 4590
 4595
 4600
 4605
 4610
 4615
 4620
 4625
 4630
 4635
 4640
 4645
 4650
 4655
 4660
 4665
 4670
 4675
 4680
 4685
 4690
 4695
 4700
 4705
 4710
 4715
 4720
 4725
 4730
 4735
 4740
 4745
 4750
 4755
 4760
 4765
 4770
 4775
 4780
 4785
 4790
 4795
 4800
 4805
 4810
 4815
 4820
 4825
 4830
 4835
 4840
 4845
 4850
 4855
 4860
 4865
 4870
 4875
 4880
 4885
 4890
 4895
 4900
 4905
 4910
 4915
 4920
 4925
 4930
 4935
 4940
 4945
 4950
 4955
 4960
 4965
 4970
 4975
 4980
 4985
 4990
 4995
 5000
 5005
 5010
 5015
 5020
 5025
 5030
 5035
 5040
 5045
 5050
 5055
 5060
 5065
 5070
 5075
 5080
 5085
 5090
 5095
 5100
 5105
 5110
 5115
 5120
 5125
 5130
 5135
 5140
 5145
 5150
 5155
 5160
 5165
 5170
 5175
 5180
 5185
 5190
 5195
 5200
 5205
 5210
 5215
 5220
 5225
 5230
 5235
 5240
 5245
 5250
 5255
 5260
 5265
 5270
 5275
 5280
 5285
 5290
 5295
 5300
 5305
 5310
 5315
 5320
 5325
 5330
 5335
 5340
 5345
 5350
 5355
 5360
 5365
 5370
 5375
 5380
 5385
 5390
 5395
 5400
 5405
 5410
 5415
 5420
 5425
 5430
 5435
 5440
 5445
 5450
 5455
 5460
 5465
 5470
 5475
 5480
 5485
 5490
 5495
 5500
 5505
 5510
 5515
 5520
 5525
 5530
 5535
 5540
 5545
 5550
 5555
 5560
 5565
 5570
 5575
 5580
 5585
 5590
 5595
 5600
 5605
 5610
 5615
 5620
 5625
 5630
 5635
 5640
 5645
 5650
 5655
 5660
 5665
 5670
 5675
 5680
 5685
 5690
 5695
 5700
 5705
 5710
 5715
 5720
 5725
 5730
 5735
 5740
 5745
 5750
 5755
 5760
 5765
 5770
 5775
 5780
 5785
 5790
 5795
 5800
 5805
 5810
 5815
 5820
 5825
 5830
 5835
 5840
 5845
 5850
 5855
 5860
 5865
 5870
 5875
 5880
 5885
 5890
 5895
 5900
 5905
 5910
 5915
 5920
 5925
 5930
 5935
 5940
 5945
 5950
 5955
 5960
 5965
 5970
 5975
 5980
 5985
 5990
 5995
 6000
 6005
 6010
 6015
 6020
 6025
 6030
 6035
 6040
 6045
 6050
 6055
 6060
 6065
 6070
 6075
 6080
 6085
 6090
 6095
 6100
 6105
 6110
 6115
 6120
 6125
 6130
 6135
 6140
 6145
 6150
 6155
 6160
 6165
 6170
 6175
 6180
 6185
 6190
 6195
 6200
 6205
 6210
 6215
 6220
 6225
 6230
 6235
 6240
 6245
 6250
 6255
 6260
 6265
 6270
 6275
 6280
 6285
 6290
 6295
 6300
 6305
 6310
 6315
 6320
 6325
 6330
 6335
 6340
 6345
 6350
 6355
 6360
 6365
 6370
 6375
 6380
 6385
 6390
 6395
 6400
 6405
 6410
 6415
 6420
 6425
 6430
 6435
 6440
 6445
 6450
 6455
 6460
 6465
 6470
 6475
 6480
 6485
 6490
 6495
 6500
 6505
 6510
 6515
 6520
 6525
 6530
 6535
 6540
 6545
 6550
 6555
 6560
 6565
 6570
 6575
 6580
 6585
 6590
 6595
 6600
 6605
 6610
 6615
 6620
 6625
 6630
 6635
 6640
 6645
 6650
 6655
 6660
 6665
 6670
 6675
 6680
 6685
 6690
 6695
 6700
 6705
 6710
 6715
 6720
 6725
 6730
 6735
 6740
 6745
 6750
 6755
 6760
 6765
 6770
 6775
 6780
 6785
 6790
 6795
 6800
 6805
 6810
 6815
 6820
 6825
 6830
 6835
 6840
 6845
 6850
 6855
 6860
 6865
 6870
 6875
 6880
 6885
 6890
 6895
 6900
 6905
 6910
 6915
 6920
 6925
 6930
 6935
 6940
 6945
 6950
 6955
 6960
 6

1 10 20 30 40 50
 CXXXXLXVXFXXDXGWXXWXXXPXGXXAXYCXGXCCXPXXXXXXXNHAXX
 60 70 80 90 100
 QXXVXXXNXXXXPXXCCXPXXXXXXXLXXXXXXVXLXXYXXMXVXXCXCX

where the letters indicate the amino acid residues of standard single letter code, and the Xs each represent any one of the 22 naturally occurring amino acid residues. Preferred amino acid sequences within the foregoing generic sequences are:

1 10 20 30 40 50
 LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
 K S S L QE VIS E FD Y E A AY MPESMKAS VI
 F E K I DN L N S Q ITK F P TL
 A S K
 60 70 80 90 100
 QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 N S K P E

and

1 10 20 30 40 50
 CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
 RRRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
 KE F E K I DN L N S Q ITK F P TL
 Q A S K
 60 70 80 90 100
 QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 N S K P E

wherein each of the amino acids arranged vertically at each position in the sequence may be used alternatively in various combinations. Note that these generic sequences have 6 and preferably 7 cysteine residues where inter- or intramolecular disulfide bonds can form, and contain other critical amino acids which influence the tertiary structure of the proteins. These generic structural features are found in previously published sequences, none of which have been described as capable of osteogenic activity, and most of which never have been linked with such activity.

[0021] Particular useful sequences include:

1 10 20 30 40
 Vg1 CKKRHLYVEFK-DVGWQNWVIAPOGYMANYCYGECPYPLTE
 5 ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
 80 90 100
 ISMLFYDNNNDNVVLRHYENMAVDECGCR

1 10 20 30 40
 DPP CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFPLAD
 15 HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
 80 90 100
 VAMLYLNDQSTVVLKKNYQEMTVVGCGCR

1 10 20 30 40
 CBMP-2a CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
 20 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
 25 80 90 100
 ISMLYLDENEKVVLKKNYQDMVVEGCGCR

1 10 20 30 40
 CBMP-2b CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
 30 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
 35 80 90 100
 ISMLYLDEYDKVVLKKNYQEMVVEGCGCR

1 10 20 30 40
 CBMP-3 CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFMPK
 40 SLKPSN--H-ATIQSIVRAVGVPGIPEPCCVPEKMSS
 45 80 90 100
 LSILFFDENKNVVLKVYPNMTVESACR

1 10 20 30 40
 COP1 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
 55 80 90 100
 ISMLYLDENSTVVLKKNYQEMTVVGCGCR

1 10 20 30 40
 COP3 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKNYQEMVVEGCGR

1 10 20 30 40
 COP4 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKNYQEMVVEGCGR

Vgl is a known Xenopus sequence heretofore not associated with bone formation. DPP is an amino acid sequence encoded by a Drosophila gene responsible for development of the dorsoventral pattern. OP1 is a region of a natural sequence encoded by exons of a genomic DNA sequence retrieved by applicants. The CBMPs are amino acid sequences comprising subparts of mammalian proteins encoded by genomic DNAs and cDNAs retrieved by applicants. The COPs are totally biosynthetic protein sequences expressed by novel consensus gene constructs, designed using the criteria set forth herein, and not yet found in nature.

[0022] These proteins are believed to be dimers. They appear not to be active when reduced. Various combinations of species of the proteins may exist as heterodimers or homodimers. As far as applicants are aware, the COP5, COP7, COP16, and OP1 constructs constitute the first instances of the design of a bioactive protein without preexisting knowledge of the active region of a native form nucleotide or amino acid sequence.

[0023] The invention thus provides synthetic osteogenic protein produced using recombinant DNA techniques. The protein may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native protein, no matter how derived. In view of this disclosure, skilled genetic engineers can design and synthesize genes which encode appropriate amino acid sequences, and then can express them in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active synthetic proteins comprising truncated analogs, muteins, fusion proteins, and other constructs mimicking the biological activity of the native forms and capable of inducing bone formation in mammals including humans.

[0024] The synthetic proteins are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles or porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The particle size should be within the range of 70 - 850 μ m, preferably 70 - 420 μ m. It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-inflammatory) and, biodegradable *in vivo* to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and particulate, deglycosylated (or HF treated), protein extracted, demineralized, xenogenic bone. Optionally, such xenogenic bone powder matrices also may be treated with proteases such as trypsin. Other useful matrix materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

[0025] The osteogenic proteins and implantable osteogenic devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial

and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1:959-963). The devices may be used to induce local endochondral bone formation in non-union fractures, and in other clinical applications including periodontal applications where bone formation is required. Another potential clinical application is in cartilage repair, for example, in the treatment of osteoarthritis.

Brief Description of the Drawing

[0026] The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1 is a comparison of the amino acid sequence of various osteogenic proteins to those of the TGF-beta family. COP1, COP3, COP4, COPS, and COP7 are a family of analogs of synthetic osteogenic proteins developed from the consensus gene that was joined to a leader protein via a hinge region having the sequence D-P-N-G that permitted chemical cleavage at the D-P site (by acid) or N-G (by hydroxylamine) resulting in the release of the analog protein; VGI is a *Xenopus* protein, DPP is a *Drosophila* protein; OP1 is a native osteogenic protein; CBMP2a and 2b, and CBMP3 are subparts of proteins disclosed in PCT application 087/01537; MIS is Mullerian inhibitory substance; and "consensus choices" represent various substitutions of amino acids that may be made at various positions in osteogenic proteins;

FIGURE 2A is an *E. coli* expression vector containing a gene of an osteogenic protein fused to a leader protein;

FIGURE 2B is the DNA sequence comprising a modified trp-LE leader, two Fb domains of protein A, an ASP-PRO cleavage site, and the COPS sequence;

FIGURES 3A and 3B are photomicrographs of implants showing the histology (day 12) of COPS active recombinant protein. A is control (rat matrix alone, 25 mg). B is rat matrix plus COP5, showing +++ cartilage formation and ++ bone formation (see key infra). Similar results are achieved with COP7; and

FIGURE 4 is a schematic representation of the DNA sequence and corresponding amino acid sequence of a consensus gene for osteogenic protein (COP0).

Description

[0027] Purification protocols have been developed which enable isolation of the osteogenic protein present in crude protein extracts from mammalian bone. The isolation procedure enables the production of significant quantities of substantially pure osteogenic protein from any mammalian species, provided sufficient amounts of fresh bone from the species is available. The empirical development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP has been characterized significantly; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat have been studied; it has been shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts; and it may be used to induce formation of endochondral bone in orthopedic defects including non-union fractures. In its native form it is a glycosylated, dimeric protein. However, it is active in deglycosylated form. It has been partially sequenced.

[0028] Elucidation of the amino acid sequence of BOP enabled the construction of a consensus nucleic acid sequence designed as disclosed herein based on the sequence data, inferred codons for the sequences, and observation of partial homology with known genes.

[0029] These consensus sequences have been refined by comparison with the sequences present in certain regulatory genes from *drosophila*, *xenopus*, and human followed by point mutation, expression, and assay for activity. This approach has been successful in producing several active totally synthetic constructs not found in nature (as far as applicants are aware) which have true osteogenic activity.

[0030] These discoveries enable the construction of DNAs encoding totally novel, non-native protein constructs which individually and combined are capable of producing true endochondral bone. The DNAs may be expressed using well established recombinant DNA technologies in procaryotic or eucaryotic host cells, and the expressed proteins may be oxidized and refolded *in vitro* if necessary for biological activity.

[0031] The design and production of such biosynthetic proteins, the nature of the matrix, and other material aspects concerning the nature, utility, how to make, and how to use the subject matter claimed herein will be further understood from the following, which constitutes the best method currently known for practicing the various aspects of the invention.

CONSENSUS SEQUENCE DESIGN

[0032] A synthetic consensus gene shown in FIGURE 4 was designed to encode a consensus protein based on amino acid predictions from homology with the TGF-beta gene family. The designed consensus sequence was then constructed using known techniques involving assembly of oligonucleotides manufactured in a DNA synthesizer.

[0033] Tryptic peptides derived from Bovine Osteogenic Protein isolated by applicants and sequenced by Edman degradation provided amino acid sequences that showed strong homology with the Drosophila DPP protein sequence (as inferred from the gene), the Xenopus VG1 protein, and somewhat less homology to inhibin and TGF-beta, as demonstrated below in TABLE 1.

TABLE 1

<u>protein</u>	<u>amino acid sequence</u>	<u>homology</u>
(BOP)	SFDAYYCSGACQFPS ***** * * *	(9/15 matches)
(DPP)	GYDAYYCHGKCPFFL	
(BOP)	SFDAYYCSGACQFPS * * * * *	(6/15 matches)
(Vql)	GYMANICYGECPYPL	
(BOP)	SFDAYYCSGACQFPS * * * * *	(5/15 matches)
(inhibin)	GYHANYCEGECPSHI	
(BOP)	SFDAYYCSGACQFPS * * * * *	(4/15 matches)
(TGF-beta)	GYHANFCLGPCPYIW	
(BOP)	K/RACCVPTELSAISMLYLDEN ***** * * * *	(12/20 matches)
(Vql)	LPCCVPTKMSPISMLFYDNN	
(BOP)	K/RACCVPTELSAISMLYLDEN * * * * *	(12/20 matches)
(inhibin)	KSCCVPTKLRPMSMLYYDDG	
(BOP)	K/RACCVPTELSAISMLYLDE **** * *	(6/19 matches)
(TGF-beta)	APCCVPQALEPLPIVYVVG	
(BOP)	K/RACCVPTELSAISMLYLDEN ***** * * *	(12/20 matches)
(DPP)	KACCVPTQLDSVAMLYLNDQ	

5 (BOP) LYVDF

 (DPP) LYVDF (5/5 matches)

10 (BOP) LYVDF
 **** *
 (Vgl) LYVEF (4/5 matches)

15 (BOP) LYVDF
 ** *
 (TGF-beta) LYIDF (4/5 matches)

20 (BOP) LYVDF
 * *
 (inhibin) FFVSF (2/5 matches)

25 *-match

30 [0034] In determining an appropriate amino acid sequence of an osteogenic protein (from which the nucleic acid sequence can be determined), the following points were considered: (1) the amino acid sequence determined by Edman degradation of natural source osteogenic protein tryptic fragments is ranked highest as long as it has a strong signal and shows homology or conservative changes when aligned with the other members of the gene family; (2) where the sequence matches for all four proteins, it is used in the synthetic gene sequence; (3) matching amino acids in DPP and Vgl are used; (4) If Vgl or DPP diverged but either one were matched by inhibin or by TGF-beta, this matched amino acid is chosen; (5) where all sequences diverged, the DPP sequence is initially chosen, with a later plan of creating the Vgl sequence by mutagenesis kept as a possibility. In addition, the consensus sequence is designed to preserve the disulfide crosslinking and the apparent structural homology among the related proteins.

40 RECOMBINANT OSTEOGENIC PROTEIN CONSTRUCTS

45 [0035] This approach resulted in the production of novel recombinant proteins capable of inducing formation of cartilage and endochondral bone comprising a protein structure analogous to or duplicative of the functional domain of the naturally sourced material. The amino acid sequences encoded by the consensus DNA sequences were derived from a family of natural proteins implicated in tissue development. These gene products/proteins are known to exist in active form as dimers and are, in general, processed from a precursor protein to produce an active C-terminal domain of the precursor.

50 [0036] The recombinant osteogenic/chondrogenic proteins are "novel" in the sense that, as far as applicants are aware, they do not exist in nature or, if they do exist, have never before been associated with bone or cartilage formation. The approach to design of these proteins is to employ amino acid sequences, found in the native OP isolates, in polypeptide structures are patterned after certain proteins reported in the literature, or the amino acid sequences inferred from DNAs reported in the literature. Thus, using the design criteria set forth above, and refining the amino acid sequence as more protein sequence information was learned, a series of synthetic proteins were designed with the hope and intent that they might have osteogenic or chondrogenic activity when tested in the bioassay system disclosed below.

55 [0037] It was noted, for example, that DPP from drosophila, VG1 from *Xenopus*, the TGF beta family of proteins, and to a lesser extent, alpha and beta inhibins, had significant homologies with certain of the sequences derived from

the naturally sourced OP product. (FIGURE 1.) Study of these proteins led to the realization that a portion of the sequence of each had a structural similarity observable by analysis of the positional relationship of cysteines and other amino acids which have an important influence on three dimensional protein conformation. It was noted that a region of these sequences had a series of seven cysteines, placed very nearly in the same relative positions, and certain other amino acids in sequence as set forth below:

```

      10      20      30      40      50
CXXXXLXVFXDXGWXXWXXXPXGXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXXNXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

wherein each X independently represents an amino acid. Expression experiments of two of these constructs demonstrate activity. Expression experiments with constructs patterned after this template amino acid sequence with a shorter sequence having only six cysteines also show activity:

```

      10      20      30      40      50
LXVFXDXGWXXWXXXPXGXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXXNXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

wherein each X independently represents an amino acid. Within these generic structures are a multiplicity of specific sequences which have osteogenic or chondrogenic activity. Preferred structures are those having the amino acid sequence:

```

      10      20      30      40      50
CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIV
RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
KE F E K I DN L N S Q ITK F P TL
Q A S K
      60      70      80      90     100
QTLVNSVNPFGKIPKACCVPTELSAISMLYLDENENVVLKQDMVVEGCGCR
SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
RF T S K DPV V Y N S H RN RS
N S K P E

```

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be used. Novel active proteins also are defined by amino acid sequences comprising an active domain beginning at residue number 6 of this sequence, i.e., omitting the N terminal CXXXX, or omitting any of the preferred specific combinations such as CKRHP, CRRKQ, CKRHE, etc., resulting in a construct having only six cysteine residues. After this work, PCT 87/01537 was published, and it was observed that the proteins there identified as BMPII a and b and BMPIII each included a region embodying this generic structure. These proteins were not demonstrated to be osteogenic in the published application. However, applicants discovered that a subpart of the amino acid sequence of these proteins, properly folded, and implanted as set forth herein, is active. These are disclosed herein as CBMPIIa, CBMPIIb, and CBMPIII. Also, applicants retrieved a previously unreported gene by probing a human genomic DNA library with COPO. This protein was designated OP1. It comprises a region exhibiting the same generic structure.

[0038] Thus, the preferred osteogenic proteins are expressed from recombinant DNA and comprise amino acid sequences including any of the following sequences:

Vg1 1 10 20 30 40
 CKKRHLVVEFK-DVGWQNWVIAPOGYMANCYGECPPYPLTE
 5 50 60 70
 ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
 80 90 100
 ISMLFYDNNNDNVVLRHYENMAVDECGCR

DPP 1 10 20 30 40
 CRRHSlyVDFS-DVGWDDWIVAPLGyDAYyCHGKCPFFPLAD
 15 50 60 70
 HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
 80 90 100
 VAMLYLNDQSTVVVLKNYQEMTVVGCGR

OP1 1 10 20 30 40
 LYVSFR-DLGWQDWIIAPEGyAAYYCEGECAPPLNS
 25 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 ISVLYFDDSSNVILKKYRNMVVVRACGCH

OP1 1 10 20 30 40
 -5
 HQRQA
 CKKHelyVSFR-DLGWQDWIIAPEGyAAYYCEGECAPPLNS
 40 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 ISVLYFDDSSNVILKKYRNMVVVRACGCH

CBMP-2a 1 10 20 30 40
 CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
 50 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQDMVVEGCGCR

CBMP-2b 1 10 20 30 40
 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA
 80 90 100
 ISMLYLDEYDKVVLKNYQEMVVEGCGCR

CBMP-3 1 10 20 30 40
 CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFPMK
 50 60 70
 SLKPSN--H-ATIQSIVRAVGVPPIPEPCCVPEKMSS
 80 90 100
 LSILFFDENKNVVLKVYPNMTVESACR

COP1 1 10 20 30 40
 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENSTVVLKNYQEMTVVGCGCR

COP3 1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR

COP4 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR

1 10 20 30 40
COP5 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
80 90 100
ISMLYLDENEKVVVLKNYQEMVVEGCGCR

1 10 20 30 40
COP7 LYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
50 60 70
HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
ISMLYLDENEKVVLKNYOEMVVEGCGCR

10.
PKHHSQRARKKNKN
1 10 20 30 40
COP16 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGECPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
ISMLYLDENEKVVLKNOEMVVEGCGCR

[0039] As shown in FIGURE 1, these sequences have considerable homology with the alpha and beta inhibins, three forms of TGF beta, and MIS.

Gene Preparation

[0040] The synthetic genes designed to express the proteins as described above preferably are produced by assembly of chemically synthesized oligonucleotides. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer (TBE). The DNA is then electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE. Natural gene sequences and cDNAs also may be used for expression.

Expression

[0041] The genes can be expressed in appropriate prokaryotic hosts such as various strains of *E. coli* and also in bacillus, yeasts, and various animal cells such as CHO, myeloma, etc. Generally, expression may be achieved using many cell types and expression systems well known to those skilled in the art. If the gene is to be expressed in *E. coli*, it must first be cloned into an expression vector. An expression vector (FIGURE 2A) based on pBR322 and containing a synthetic trp promoter operator and the modified trp LE leader can be opened at the EcoRI and PSTI restriction sites, and a FB-FB COP1, COP3, COPS, and COP7 gene fragments (FIGURE 2B) can be inserted between these sites, where FB is fragment B of Staphylococcal Protein A. The expressed fusion protein results from attachment of the COP gene to a fragment encoding FB. The COP protein is joined to the leader protein via a hinge region having the sequence Asp-Pro-Asn-Gly. This hinge permits chemical cleavage of the fusion protein with dilute acid at the asp-pro site or cleavage at Asn-Gly with hydroxylamine, resulting in release of the COP protein. For COP16 and OP1, the proteins are expressed as fusion products, using the modified trp-LE as a leader.

Production of Active Proteins

[0042] The following procedure was followed for production of active recombinant proteins. *E. coli* cells containing the fusion proteins were lysed. The fusion proteins were purified by differential solubilization. In the case of the COP1, 3, 4, 5, and 7 fusion proteins, cleavage was with dilute acid, and the resulting cleavage products were passed through a Sephacryl-200HR column. The Sephacryl column separated most of the uncleaved fusion products from the COP1, 3, 4, 5, and 7 analogs. In the case of the COP16 or OP1 fusion protein, cleavage was with a more concentrated acid, and an SP-Trisacryl column was used as an additional purification step. The COP or OP fractions were then subjected to HPLC on a semi-prep C-18 column.

[0043] Initial conditions for refolding of COP analogs or OP1 were at pH 8.0 using Tris, Gu-HCl, dithiothreitol. Final conditions for refolding of COP analogs were at pH 8.0 using Tris, oxidized glutathione, and lower amounts of Gu-HCl and dithiothreitol. Alternatively, the COP or OP1 proteins are suspended in 50 mM HCl, 6 M guanidine-HCl, pH 8.0, for 18 hours at 4°C. Refolding may not be required if the proteins are expressed in animal cells.

Production of Antisera

[0044] Antisera to COP7 and COPS were produced in New Zealand white rabbits. Western blots demonstrate that the antisera react with COP7 and COPS preparations. Antisera to COP7 has been tested for reactivity to naturally sourced bovine osteogenic protein samples. Western blots show a clear reaction with the 30 kD protein and, when reduced, with the 16 kD subunit. The immunoreactive species appears as a closely-spaced doublet in the 16 kD subunit region, similar to the 16 kD doublet seen in Con A blots.

MATRIX PREPARATIONGeneral Consideration of Matrix Properties

[0045] The carrier described in the bioassay section, *infra*, may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., HAP, collagen, tricalcium phosphate, or polylactic acid, polyglycolic acid and various copolymers thereof). Also xenogeneic bone may be used if pretreated as described below.

[0046] Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 and 420 μ m elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate osteogenic protein onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

[0047] The sequential cellular reactions at the interface of the bone matrix/OP implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

[0048] A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be biocompatible *in vivo* and biodegradable; the carrier must act as a temporary scaffold until replaced completely by new bone. Biocompatibility requires that the matrix not induce significant inflammation when implanted and not be rejected by the host animal. Biodegradability requires that the matrix be slowly absorbed by the body of the host during development of new bone or cartilage. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates *in vivo*. In bones, the dissolution rates can vary according to whether the implant is placed in cortical or trabecular bone.

[0049] Matrix geometry, particle size, the presence of surface charge, and porosity or the presence of interstices among the particles of a size sufficient to permit cell infiltration, are all important to successful matrix performance. It is preferred to shape the matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

[0050] The matrix may comprise a shape-retaining solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue. Masticated muscle or other tissue may also be used. Large allogeneic bone implants can act as a carrier for the matrix if their marrow cavities are cleaned and packed with particles and the dispersed osteogenic protein.

Preparation of Biologically Active Allogenic Matrix

[0051] Demineralized bone matrix is prepared from the dehydrated diaphyseal shafts of rat femur and tibia as described herein to produce a bone particle size which pass through a 420 μm sieve. The bone particles are subjected to dissociative extraction with 4 M guanidine-HCl. Such treatment results in a complete loss of the inherent ability of the bone matrix to induce endochondral bone differentiation. The remaining insoluble material is used to fabricate the matrix. The material is mostly collagenous in nature, and upon implantation, does not induce cartilage and bone. All new preparations are tested for mineral content and false positives before use. The total loss of biological activity of bone matrix is restored when an active osteoinductive protein fraction or a pure protein is reconstituted with the biologically inactive insoluble collagenous matrix. The osteoinductive protein can be obtained from any vertebrate, e.g., bovine, porcine, monkey, or human, or produced using recombinant DNA techniques.

Preparation of Deglycosylated Bone Matrix for Use in Xenogenic Implant

[0052] When osteogenic protein is reconstituted with collagenous bone matrix from other species and implanted in rat, no bone is formed. This suggests that while the osteogenic protein is xenogenic (not species specific), while the matrix is species specific and cannot be implanted cross species perhaps due to intrinsic immunogenic or inhibitory components. Thus, heretofore, for bone-based matrices, in order for the osteogenic protein to exhibit its full bone inducing activity, a species specific collagenous bone matrix was required.

[0053] The major component of all bone matrices is Type I collagen. In addition to collagen, extracted bone includes non-collagenous proteins which may account for 5% of its mass. Many non-collagenous components of bone matrix are glycoproteins. Although the biological significance of the glycoproteins in bone formation is not known, they may present themselves as potent antigens by virtue of their carbohydrate content and may constitute immunogenic and/or inhibitory components that are present in xenogenic matrix.

[0054] It has now been discovered that a collagenous bone matrix may be used as a carrier to effect bone inducing activity in xenogenic implants, if one first removes the immunogenic and inhibitory components from the matrix. The matrix is deglycosylated chemically using, for example, hydrogen fluoride to achieve this purpose.

[0055] Bovine bone residue prepared as described above is sieved, and particles of the 74-420 μm are collected. The sample is dried in vacuo over P_2O_5 , transferred to the reaction vessel and anhydrous hydrogen fluoride (HF) (10-20 ml/g of matrix) is then distilled onto the sample at -70°C . The vessel is allowed to warm to 0°C . and the reaction mixture is stirred at this temperature for 120 min. After evaporation of the HF in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid.

[0056] Extent of deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with HF, after washing the samples appropriately to remove non-covalently bound carbohydrates.

[0057] The deglycosylated bone matrix is next treated as set forth below:

1) suspend in TBS (Tris-buffered Saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) and stir at RT for 30 min;

2) centrifuge and wash with TBS or UTBS as in step 1; and

3) centrifuge; discard supernatant; water wash residue; and then lyophilize.

FABRICATION OF DEVICE

[0058] Fabrication of osteogenic devices using any of the matrices set forth above with any of the osteogenic proteins described above may be performed as follows.

A. Ethanol precipitation

[0059] In this procedure, matrix is added to osteogenic protein in guanidine-HCl. Samples are vortexed and incubated at a low temperature. Samples are then further vortexed. Cold absolute ethanol is added to the mixture which is then stirred and incubated. After centrifugation (microfuge high speed) the supernatant is discarded. The reconstituted matrix is washed with cold concentrated ethanol in water and then lyophilized.

B. Acetonitrile Trifluoroacetic Acid Lyophilization

[0060] In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution is added to the

carrier. Samples are vigorously vortexed many times and then lyophilized.

C. Urea Lyophilization

- 5 [0061] For those proteins that are prepared in urea buffer, the protein is mixed with the matrix, vortexed many times, and then lyophilized. The lyophilized material may be used "as is" for implants.

IN VIVO RAT BIOASSAY

- 10 [0062] Several of the synthetic proteins have been incorporated in matrices to produce osteogenic devices, and assayed in rat for endochondral bone. Studies in rats show the osteogenic effect to be dependent on the dose of osteogenic protein dispersed in the osteogenic device. No activity is observed if the matrix is implanted alone. The following sets forth guidelines for how the osteogenic devices disclosed herein can be assayed for evaluating protein constructs and matrices for biological activity.

15 A. Subcutaneous Implantation

- [0063] The bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80: 6591-6595), herein incorporated by reference, is used to assess endochondral bone differentiation activity. This assay consists of implanting the test samples in subcutaneous sites in allogenic recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is designated as day one of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

B. Cellular Events

- 30 [0064] The implant model in rats exhibits a controlled progression through the stages of matrix induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

C. Histological Evaluation

- 40 [0065] Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Implants are fixed in Bouins Solution, embedded in parafilm, cut into 6-8 mm sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of endochondral bone. Twelve day implants are usually sufficient to determine whether the implants show bone inducing activity.

D. Biological Markers

- 45 [0066] Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be determined Spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days *in vivo* and thereafter slowly declines. Implants showing no bone development by histology should have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the implants are removed from the rat. Alternatively the amount of bone formation can be determined by measuring the calcium content of the implant.

[0067] The osteogenic activity due to osteogenic protein is represented by "bone forming units". One bone forming unit represents the amount of protein that is needed for half maximal bone forming activity as compared to rat demineralized bone matrix as control and determined by calcium content of the implant on day 12.

- 55 [0068] Devices that contained only rat carrier show complete absence of new bone formation. The implant consists of carrier rat matrix and surrounding mesenchymal cells. Again, the devices that contained rat carrier and not correctly folded (or biologically inactive) recombinant protein also showed complete absence of bone formation. These implants are scored as cartilage formation (-) and bone formation (-). The endochondral bone formation activity is scored as

zero percent (0%) (FIGURE 3A).

[0069] Implants included biologically active recombinant protein, however, showed evidence of endochondral bone formation. Histologically they showed new cartilage and bone formation.

[0070] The cartilage formation is scored as (+) by the presence of metachromatically stained chondrocytes in the center of the implant, as (++) by the presence of numerous chondrocytes in many areas of the implant and as (+++) by the presence of abundant chondrocytes forming cartilage matrix and the appearance of hypertrophied chondrocytes accompanying cartilage calcification (FIGURE 3B).

[0071] The bone formation is scored as (+) by the presence of osteoblast surrounding vascular endothelium forming new matrix, as (++) by the formation of bone due to osteoblasts (as indicated by arrows) and further bone remodeling by the appearance of osteoclasts in opposition to the newly formed bone matrix. Vascular invasion is evident in these implants (FIGURE 3B). Formation is scored as (+++) by the presence of extensive remodeled bone which results in the formation of ossicles.

[0072] The overall bone inducing activity due to recombinant protein is represented as percent response of endochondral bone formation (see TABLE 2 below).

TABLE 2

HISTOLOGICAL EVALUATION OF RECOMBINANT BONE INDUCTIVE PROTEINS			
Sample No.	Implanted Protein	Cartilage Formation	Bone Formation.
260-54	COP-5	+++	++
279-5	COP-5	++	+
285-13	COP-5	+++	++
277-7	COP-7	+++	++
277-8	COP-7	+++	++
277-9	COP-7	++	+
285-14	COP-7	+++	++
285-24	COP-7	++	+
285-25	COP-7	++	++
314-6	COP-16	+++	+++
314-15	COP-16	++	+
314-16	COP-16	++	+
314-12	OP-1	++	+

[0073] The invention relates to an osteogenic device for implantation in a mammal, said device comprising a biocompatible, *in vivo* biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains, each of which comprises an amino acid sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing endochondral bone formation in association with said matrix when implanted in a mammal.

[0074] Also covered by the invention is a device for implantation in a mammal, said device comprising a biocompatible, *in vivo* biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains, each of which has less than about 200 amino acids, and each of which comprises a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing cartilage formation in association with said matrix when implanted in a mammal.

[0075] The sequence may comprise

```

      10      20      30      40      50
CXXXLXVXFEXGWWXXXPXGXXAXCXGXCPXXXXXXNHAXX
      60      70      80      90     100
QXXVXXNXXXPXXCCPXXXXXXXXLXXXXXXXXVXLXXYXXDXVXXCX

```

wherein each X independently represents an amino acid; or

5 10 20 30 40 50
 LXVXFDXGWXXWXXXPXGXAXYCXXGXCPXXXXXXNHAIX
 60 70 80 90 100
 QXXVXXNXXXXPXXCCXPXXXXXXLXXXXXXVXLXXYXXMXVXXCX

10 wherein each X independently represents an amino acid; or

15 10 20 30 40 50
 CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECFPFLADHLNSTNHAIV
 RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
 KE F E K I DN L N S Q ITK F P TL
 Q A S K
 60 70 80 90 100
 20 QTLVNSVNP GKIPKACCVPTLSAISMLYLDENENVVLKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 N S K P E

25 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

30 10 20 30 40 50
 LYVDFRDVGWNDWIVAPPGYHAFYCHGECFPFLADHLNSTNHAIV
 K S S L QE VIS E FD Y E A AY MPESMKAS VI
 F E K I DN L N S Q ITK F P TL
 A S K
 60 70 80 90 100
 35 QTLVNSVNP GKIPKACCVPTLSAISMLYLDENENVVLKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 40 N S K P E

45 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

50 1 10 20 30 40
 Vg1 CKKRHLVVEFK-DVGWQNWVIAPQGYMANYCYGECPYPLTE
 50 60 70
 55 ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
 80 90 100
 ISMLFYDNNNDNVVLRHYENMAVDECGCR

or

5
DPP 1 10 20 30 40
CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFLAD
50 60 70
HFNSTN--H-AIVQTLVNNNNPGK-VPKACCVPTQLDS
80 90 100
10 VAMLYLNDQSTVVLKQEMTVVGCGCR

or

15
OP1 1 10 20 30 40
LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
50 60 70
20 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
ISVLYFDDSSNVILKKYRNMVVRACGCH

25 or

30
OP1 1 10 20 30 40
CKKHLYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
35 ISVLYFDDSSNVILKKYRNMVVRACGCH

or

40
CBMP-2a 1 10 20 30 40
CKRHPLYVDFS-DVGWDDWIVAPPGYHAFYCHGECPPFLAD
50 60 70
45 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTQLSA
80 90 100
ISMLYLDENEKVVLKQDMVVEGCGCR

or

50
CBMP-2b 1 10 20 30 40
CRRHSLYVDFS-DVGWDDWIVAPPGYQAFYCHGDCPPFLAD
50 60 70
55 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTQLSA
80 90 100
ISMLYLDYDKVVLKQEMVVEGCGCR

or

5 CBMP-3 1 10 20 30 40
 CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFPMFK
 50 60 70
 SLKPSN--H-ATIQSIVRAVGVPPIPEPCCVPEKMSS
 80 90 100
 10 LSILFFDENKNVVLKVYPNMTVESACR

or

15 COP1 1 10 20 30 40
 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 20 ISMLYLDENSTVVLKNYQEMTVVGCGCR

or

25 COP3 1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 30 80 90 100
 ISMLYLDENKVVVLKNYQEMVVEGCGCR

35 or

40 COP4 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENKVVVLKNYQEMVVEGCGCR

45 or

50 COP5 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECFPLAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 55 ISMLYLDENKVVVLKNYQEMVVEGCGCR

or

COP7 1 10 20 30 40
LYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
50 60 70
HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
ISMLYLDENEKVVLKNYQEMVVEGCGCR

or

10
PKHHSQRARKKNKN
1 10 20 30 40
COP16 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGECPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
ISMLYLDENEKVVLKNYQEMVVEGCGCR

[0076] The device of the invention may comprise an osteogenic protein comprising a pair of separate polypeptide chains.

[0077] The invention also relates to an osteogenic protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains each of which comprises a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing endochondral bone formation in association with a matrix when implanted in a mammal.

[0078] In another embodiment, the invention relates to a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains less than about 200 amino acids long and comprising a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing cartilage formation in association with a matrix when implanted in a mammal.

[0079] The protein may be unglycosylated, and may comprise the amino acid sequences:

10 20 30 40 50
 CXXXLXVFXDXGWXXWXXXPXGXAXYCXGXCPXXXXXXNHAXX
 60 70 80 90 100
 QXXVXXNXNXXXPXXCXPXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

or

10 20 30 40 50
LXVFXDXGWXXWXXXPXGXAXYCXGXCPXXXXXXXXNHAXX
60 70 80 90 100
QXXVXXNXXPXCCPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

wherein each X independently represents an amino acid.

[0080] The protein of the invention may comprise the amino acid sequences:

10 20 30 40 50
 CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
 RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
 5 KE F E K I DN L N S Q ITK F P TL
 Q A S K
 60 70 80 90 100
 QTLVNSVNPFGKIPKACCVPTELSAISMLYLDENENVVLKKNYQDMVVEGCGCR
 10 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 N S K P E

15 wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

[0081] The protein of the invention may comprise the amino acid sequences:

10 20 30 40 50
 LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
 K S S L QE VIS E FD Y E A AY MPESMKAS VI
 F E K I DN L N S Q ITK F P TL
 A S K
 25 60 70 80 90 100
 QTLVNSVNPFGKIPKACCVPTELSAISMLYLDENENVVLKKNYQDMVVEGCGCR
 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 30 N S K P E

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

[0082] The protein of the invention may comprise the amino acid sequences:

1 10 20 30 40
 40 Vgl CKKRHLYVEFK-DVGWQNWVIAPOGYMANYCYGECPPYPLTE
 50 60 70
 ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
 80 90 100
 ISMLFYDNNNDNVVLRYENMAVDECGCR

or

1 10 20 30 40
 50 DPP CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFLAD
 50 60 70
 HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
 80 90 100
 55 VAMLYLNDQSTTVVLKKNYQEMTVVGGCGCR

or

1 10 20 30 40
 OP1 LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
 5 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 ISVLYFDDSSNVILKKYRNMVVRACGCH

10 or

15 -5
 HQRQA
 1 10 20 30 40
 OP1 CKKHLYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 20 80 90 100
 ISVLYFDDSSNVILKKYRNMVVRACGCH

25 or

1 10 20 30 40
 CBMP-2a CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQDMVVEGCGCR

35 or

40 1 10 20 30 40
 CBMP-2b CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA
 45 80 90 100
 ISMLYLDYDKVVLKNYQEMVVEGCGCR

50 or

55

5 CBMP-3 1 10 20 30 40
CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFMPK
50 60 70
SLKPSN--H-ATIQSIVRAVGVPGEPEPCCVPEKMSS
80 90 100
LSILFFDENKNVVLKVYPNMTVESACR

or

15 COP1 1 10 20 30 40
LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
20 80 90 100
ISMLYLDENSTVVLKKNYQEMTVVGCGR

or

25 COP3 1 10 20 30 40
LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
30 80 90 100
ISMLYLDENEKVVLKKNYQEMVVEGCGR

or

40
45 COP4 1 10 20 30 40
LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
50 60 70
HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
80 90 100
50 ISMLYLDENEKVVLKKNYQEMVVEGCGR

or

1 10 20 30 40
COP5 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPFPLAD
50 60 70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
ISMLYLDENEKVVLKNYOEMVVEGCGCR

1 10 20 30 40
COP7 LYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
50 60 70
HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
80 90 100
ISMLYLDENEKVVLKNYQEMVVEGCGCR

-10
 PKHSSSRARKKNKN
 1 10 20 30 40
 COP16 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGECPFPLAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR

- [0083] The protein of the invention may comprise the product of expression of a DNA in a procaryotic cell.
[0084] Also contemplated by the invention is a cell line engineered to express the protein of the invention.
[0085] Preferably, the protein has a half maximum bone forming activity of about 20-25 ng per 25 mg of implant.
[0086] The invention also contemplates antibodies reactive with an epitope of the protein of the invention.
[0087] The device of the invention preferably includes a matrix comprising demineralized, deglycosylated, protein extracted, particulate, xenogenic bone, or demineralized, protein extracted, particulate, xenogenic bone treated with HF.

Claims

1. Osteogenic protein comprising a pair of polypeptide chains bonded in the unreduced state to form a homo- or heterodimeric species having a conformation such that the pair of polypeptide chains is capable of inducing endochondral bone formation when disposed within a matrix and implanted in a mammal, wherein the protein comprises a region containing six cysteine residues positioned in the relative positions shown in the sequence:

LXVFXDXGWXXWXXXPXGXXAXYCXGXCPXXXXXXXNHAXXQXXVX
XXNXXXXPXCCPXXXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX,

wherein the letters indicate the amino acid residues of standard single letter code and each X represents any amino acid, with the proviso that dpp is excluded.

2. The protein of claim 1 wherein the protein comprises a region containing seven cysteine residues positioned in the relative positions shown in the sequence:

5

CXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
QXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX.

10

3. The protein of claim 1 or claim 2 which is a recombinant protein produced by expression in a host cell.
4. A process for producing active synthetic osteogenic protein as defined in claim 1, said protein comprising a pair of polypeptide chains disulphide bonded to produce a dimeric species, the process comprising the steps of:

15

(a) producing a consensus amino acid sequence by comparing amino acid sequences of proteins of the TGF-beta gene family, which consensus sequence preserves the disulphide crosslinking pattern present in the sequence:

20

(i) LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXN
HAXXQXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXL
XXYXXMXVXXCXCX;

25

or

30

(ii) CXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXX
XXXXNHAXXQXXVXXNXXXXPXXCCXPXXXXXXXXLXXXX
XXVXLXXYXXMXVXXCXCX;

35

wherein the letters indicate the amino acid residues of standard single letter code and each X represents any amino acid;

40

(b) constructing a synthetic gene encoding the consensus amino acid sequence of step (a), for example by assembling chemically synthesised oligonucleotides;

(c) introducing the synthetic gene of step (b) into a prokaryotic or eukaryotic host cell;

(d) expressing the synthetic gene to produce a putative synthetic osteogenic protein;

45

(e) assaying the putative synthetic osteogenic protein to determine whether it is active in inducing endochondral bone formation when implanted in a mammal, and optionally

(f) repeating steps (a) to (e) (or mutagenizing the synthetic gene and repeating steps (c) to (e) if the putative synthetic osteogenic protein is inactive when so assayed.

50

5. The process of claim 4 wherein the consensus nucleic acid sequence comprises the sequence:

55

(a) LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXN
HAXXQXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXL
XXYXXMXVXXCXCX;

or

(b) CXXXLXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXX
 XXXXNHAXXQXXVXXXNXXXXPXXCCXPXXXXXXXXXXLXXXXX
 XXVXLXXYXXMXVXXCXCX;

wherein the letters indicated the amino acid residues of standard single letter code and each X represents any amino acid.

6. The process of any one of claims 4-5 wherein the synthetic gene of step (b) comprises a nucleotide sequence which encodes a synthetic polypeptide chain having the same number of cysteine residues in the same relative positions as COPS, COP7, COP16 or OP1.
7. The process of any one of claims 4-6 wherein the synthetic gene of step (b) comprises a nucleotide sequence which encodes a synthetic polypeptide chain sharing one or more amino acids at corresponding positions in any of the sequences: Vg1, DPP, OP1, CBMP-2a, CBMP-2b, CBMP-3, COP1, COP3, COP4, COPS, COP7 or COP16.
8. The process of any one of claims 4-7 wherein the synthetic gene of step (b) comprises a nucleotide sequence which encodes a synthetic polypeptide chain comprising the amino acid sequence:

(a)

10	20	30	40	50
CKRHPLYVDFRDVGW	NDWIVPPGYHAFYCH	GECPPFLADHLNSTN	HAIV	
RKRS K S S L QE	VIS E FD Y E A	AY MPESMKAS	VI	
KE F E K I DN	L N S Q	ITK F P	TL	
Q	A S K			
60	70	80	90	100
QTLVNSVNP	PGKIPKACCVPT	ELSAISMLYLDEN	ENVVLKKNYQDM	VVEGCGCR
SI HAI SEQV EP	A EQMNSLAI	FFNDQDK I RK	EE T DA H H	
RF T S	K DPV V Y N S	H RN RS		
N S		K P E		

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

(b)

10	20	30	40	50
LYVDFRDVGW	NDWIVAPPGYHAFYCH	GECPPFLADHLNSTN	HAIV	
K S S L QE	VIS E FD Y E A	AY MPESMKAS	VI	
F E K I DN	L N S Q	ITK F P	TL	
A S K				
60	70	80	90	100
QTLVNSVNP	PGKIPKACCVPT	ELSAISMLYLDEN	ENVVLKKYQDM	VVEGCGCR
SI HAI SEQV EP	A EQMNSLAI	FFNDQDK I RK	EE T DA H H	
RF T S	X DPV V Y N S	H RN RS		
N S		K P E		

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position; or

(c)

1 10 20 30 40
 CRRHSLYVDFS-DVGWDDWIVAPLGIDAYYCHGKCPFPLAD
 50 60 70
 HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
 80 90 100
 VAMLYLNDQSTVVLKNIQEMTVVGCGCR; or

(d)

1 10 20 30 40
 LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 ISVLYFDDSSNVILKKYRNMVVRACGCH; or

(e)

-5
 HQRQA
 1 10 20 30 40
 CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 ISVLYFDDSSNVILKKYRNMVVRACGCH; or

(f)

1 10 20 30 40
 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPGR-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENSTVVLKNYQEMTVVGCGR; or

(g)

1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPGR-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKNYQEMVVEGCGCR; or

(h)

1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPGR-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKYQEMVVEGCGCR.

9. The protein of any one of claims 1-3 wherein the protein comprises a synthetic polypeptide chain of less than 200 amino acids.
10. The process of any one of claims 4-8 wherein the protein comprises a synthetic polypeptide chain of less than 200 amino acids.
11. The protein of claim 3 wherein the host cell is a prokaryotic or eukaryotic host cell, for example E. coli, bacillus, yeasts or animal cells (e.g. CHO or myeloma).
12. The process of any one of claims 4-8 or 10 wherein the host cell is a prokaryotic or eukaryotic host cell, for example

E. coli, bacillus, yeasts or animal cells (e.g. CHO or myeloma).

13. The protein of any one of claims 1-3 wherein the protein is unglycosylated.
- 5 14. The process of any one of claims 4-8 or 10 wherein the protein is unglycosylated:
15. A composition comprising protein comprising a pair of polypeptide chains disulphide bonded to produce a dimeric species, the protein being as defined in claim 1, 2 or 3.
- 10 16. An osteogenic device comprising a matrix in which is disposed the protein of claim 1, 2 or 3.
17. An osteogenic device for implantation in a mammal, the device comprising: (a) a biocompatible, in vivo biodegradable matrix defining a scaffold of dimensions sufficient to permit the attachment, proliferation and differentiation of migratory progenitor cells from the body of said mammal, and (b) the protein of claim 1, 2 or 3 disposed in said
15 matrix and accessible to said cells.
18. The device of claim 16 or claim 17 wherein said matrix comprises close-packed particulate matter having a particle size within the range of 70 to 850 μm (e.g. 70 to 420 μm).
- 20 19. The device of any one of claims 16-18 wherein said matrix comprises: (a) allogenic bone, e.g. demineralized, protein extracted, particulate, allogenic bone, (b) demineralized, protein extracted, particulate, deglycosylated xenogenic bone, (c) demineralized, protein extracted, particulate xenogenic bone treated with HF or a protease, (d) materials selected from collagen, hydroxyapatite, calcium phosphates (e.g. tricalcium phosphate) and polymers comprising glycolic acid and/or lactic acid monomers, (e) a shape-retaining solid of loosely adhered particulate
25 material e.g. collagen, (f) a porous solid or (g) masticated tissue, e.g. muscle.
20. The device of any one of claims 16 to 19 disposed within the marrow cavity of allogenic bone.
21. The device of any of claims 16 to 20 for use in therapy, e.g. for inducing local cartilage and/or endochondral or
30 heterotopic bone formation in a mammal by implanting the device in a mammal at a locus accessible to migratory progenitor cells.
22. The device of claim 21 for the formation of shaped heterotopic bone, wherein the shape of the heterotopic bone formed conforms to that of the implanted device.
- 35 23. Use of the protein of claim 1, 2 or 3 for the manufacture of: (a) a device according to any of claims 16 to 21, or (b) a medicament, the medicament or device being for inducing local cartilage and/or endochondral or heterotopic bone formation in a mammal by introducing the medicament or device in a mammal at a locus accessible to migratory progenitor cells for periodontal treatment, cartilage repair and for the treatment of osteoarthritis or to correct
40 non-union fractures, acquired or congenital craniofacial and other skeletal or dental anomalies.
24. The use of claim 23 for the formation of shaped heterotopic bone, wherein the shape of the heterotopic bone formed conforms to that of the implanted device.
- 45 25. A synthetic nucleic acid molecule for use in the process of any one of claims 4 to 8.
26. A host cell for use in the process of any one of claims 4 to 8 which contains the synthetic nucleic acid molecule of claim 25.
- 50 27. The host cell of claim 26 which is a prokaryotic or eukaryotic host cell, for example E. coli, bacillus, yeasts or animal cells (e.g. CHO or myeloma).
28. An isolated DNA sequence which encodes the amino acid sequence of the protein as defined in any one of claims
55 1-3 or 9.

Patentansprüche

1. Osteogenes Protein, das zwei Polypeptidketten umfasst, die im nicht-reduzierten Zustand gebunden sind, so dass sie eine homo- oder heterodimere Spezies mit einer solchen Konformation bilden, dass die zwei Polypeptidketten dazu in der Lage sind, eine Ersatzknochenbildung zu induzieren, wenn sie in einer Matrix angeordnet und einem Säugetier implantiert werden, wobei das Protein einen Bereich umfasst, der sechs Cystein-Reste enthält, die in den in der Sequenz dargestellten relativen Positionen angeordnet sind:

LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXXQXXVX
 XXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX;

wobei die Buchstaben die Aminosäurereste im Standard Ein-Buchstaben-Code angeben und jedes X irgendeine Aminosäure repräsentiert, unter dem Vorbehalt, dass dpp ausgenommen ist.

2. Protein nach Anspruch 1, wobei das Protein einen Bereich umfasst, der sieben Cystein-Reste enthält, die in den in der Sequenz dargestellten relativen Positionen angeordnet sind:

CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXX
 QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX.

3. Protein nach Anspruch 1 oder Anspruch 2, das ein rekombinantes Protein ist, das durch Expression in einer Wirtszelle hergestellt wird.
4. Verfahren zur Herstellung eines aktiven synthetischen osteogenen Proteins, wie in Anspruch 1 definiert, wobei das Protein zwei Polypeptidketten umfasst, die durch Disulfidbrücken verbunden sind, so dass eine dimere Spezies erzeugt wird, wobei das Verfahren die folgenden Schritte umfasst:

(a) Erzeugen einer Aminosäure-Consensussequenz durch Vergleich von Aminosäuresequenzen von Proteinen der TGF-beta-Genfamilie, wobei die Consensussequenz das Disulfidvernetzungsmuster erhält, das in der folgenden Sequenz vorliegt:

(i) LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXN
 HAXXQXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXL
 XXYXXMXVXXCXCX;

oder

(ii) CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXX
 XXXXNHAXXQXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXX
 XXVXLXXYXXMXVXXCXCX;

wobei die Buchstaben die Aminosäurereste im Standard Ein-Buchstaben-Code anzeigen und jedes X irgendeine Aminosäure repräsentiert;

(b) Konstruieren eines synthetischen Gens, das die Aminosäure-Consensussequenz von Schritt (a) kodiert,

beispielsweise durch Zusammenfügen von chemisch synthetisierten Oligonukleotiden;

(c) Einbringen des synthetischen Gens aus Schritt (b) in eine prokaryontische oder eukaryontische Wirtszelle;

(d) Exprimieren des synthetischen Gens zur Erzeugung eines putativen synthetischen osteogenen Proteins;

(e) Untersuchen des putativen synthetischen osteogenen Proteins, um zu bestimmen, ob es zur Induktion einer Ersatzknochenbildung wirksam ist, wenn es einem Säugetier implantiert wird, und wahlweise

(f) Wiederholen der Schritte (a) bis (e) (oder Mutagenisieren des synthetischen Gens und Wiederholen der Schritte (c) bis (e), wenn das putative synthetische osteogene Protein inaktiv ist, wenn es so geprüft wird).

5. Verfahren nach Anspruch 4,
wobei die Nukleinsäure-Consensussequenz die folgende Sequenz umfasst:

(a) LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXN
HAXXQXXVXXNXNXXXPXXCCXPXXXXXXXXLXXXXXXXXVXL
XXYXXMXVXXCXCX;

oder

(b) CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXX
XXXXNHAXXQXXVXXNXNXXXPXXCCXPXXXXXXXXLXXXX
XXVXLXXYXXMXVXXCXCX;

wobei die Buchstaben die Aminosäurereste im Standard Ein-Buchstaben-Code angeben und jedes X irgendeine Aminosäure repräsentiert.

6. Verfahren nach einem oder mehreren der Ansprüche 4 bis 5,
wobei das synthetische Gen aus Schritt (b) eine Nukleotidsequenz umfasst, die eine synthetische Polypeptidkette mit derselben Anzahl an Cystein-Resten in denselben relativen Positionen kodiert, wie COP5, COP7, COP16 oder OP1.
7. Verfahren nach irgendeinem der Ansprüche 4 bis 6,
wobei das synthetische Gen aus Schritt (b) eine Nukleotidsequenz umfasst, die eine synthetische Polypeptidkette kodiert, die eine oder mehrere Aminosäuren an den entsprechenden Positionen in irgendeiner der Sequenzen: Vg1, DPP, OP1, CBMP-2a, CMBP-2b, CBMP-3, COP1, COP3, COP4, COP5, COP7 oder COP16, umfasst.
8. Verfahren nach einem der Ansprüche 4 bis 7,
wobei das synthetische Gen aus Schritt (b) eine Nukleotidsequenz umfasst, die eine synthetische Polypeptidkette kodiert, die die folgende Aminosäure umfasst:

(a)

	10	20	30	40	50
	CKRHPLYVDFRDVGWNDWIVPPGYHAFYCHGECPFPLADHLNSTNHAIV				
5	RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI				
	KE F E K I DN L N S Q ITK F P TL				
	Q A S K				
	60	70	80	90	100
10	QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR				
	SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H				
	RF T S K DPV V Y N S H RN RS				
	N S K P E				

wobei in jeder Position, in der mehr als eine Aminosäure dargestellt ist, irgendeine der dargestellten Aminosäuren in dieser Position vorliegen kann; oder

(b)

	10	20	30	40	50
	LYVDFRDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIV				
25	K S S L QE VIS E FD Y E A AY MPESMKAS VI				
	F E K I DN L N S Q ITK F P TL				
	A S K				
	60	70	80	90	100
30	QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKRYQDMVVEGCGCR				
	SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H				
	RF T S X DPV V Y N S H RN RS				
	N S K P E				

wobei in jeder Position, in der mehr als eine Aminosäure dargestellt ist, irgendeine der dargestellten Aminosäuren in dieser Position vorliegen kann; oder

(c)

	1	10	20	30	40
45	CRRHSLYVDFS-DVGWDDWIVAPLG YDAY YCHGKCPFLAD				
		50	60	70	
	HENSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS				
50		80	90	100	
	VAMLYLNDQSTVVLKNYQEMTVVGGCGCR;				

oder

(d)

5
1 10 20 30 40
LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
10 50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
ISVLYFDDSSNVILKKYRNMVVRACGCH;

oder

(e)

20
-5
25 HORQA
1 10 20 30 40
CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
30 50 60 70
YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
80 90 100
ISVLYFDDSSNVILKKYRNMVVRACGCH;

oder

(f)

40
45 1 10 20 30 40
LYVDFQRDVGWDDWIIAPVDFDAYYCAGQFPSAD
50 50 60 70
HFNSTN--H-AVVQTLVNNMNPGR-VPKPCCVPTLSA
80 90 100
ISMLYLDENSTVVLKNYQEMTVVGCGCR;

oder

(g)

1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPVKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR;

oder

(h)

1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPVKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR.

9. Protein nach einem der Ansprüche 1 bis 3,
wobei das Protein eine synthetische Polypeptidkette von weniger als 200 Aminosäuren umfasst.
10. Verfahren nach einem der Ansprüche 4 bis 8,
wobei das Protein eine synthetische Polypeptidkette von weniger als 200 Aminosäuren umfasst.
11. Protein nach Anspruch 3,
wobei die Wirtszelle eine prokaryontische oder eukaryontische Wirtszelle ist, beispielsweise E. coli, Bacillus, Hefen
oder Tierzellen (beispielsweise CHO oder Myeloma).
12. Verfahren nach einem der Ansprüche 4 bis 8 oder 10,
wobei die Wirtszelle eine prokaryontische oder eukaryontische Wirtszelle ist, beispielsweise E. coli, Bacillus, Hefen
oder Tierzellen (beispielsweise CHO oder Myeloma).
13. Protein nach einem der Ansprüche 1 bis 3,
wobei das Protein unglykosyliert ist.
14. Verfahren nach einem der Ansprüche 4 bis 8 oder 10,
wobei das Protein unglykosyliert ist.
15. Zusammensetzung, die ein Protein umfasst, dass zwei Polypeptidketten, die durch Disulfidbrücken verbunden
sind, umfasst, um eine dimere Spezies zu erzeugen, wobei das Protein wie in Anspruch 1, 2 oder 3 definiert ist.

16. Osteogene Vorrichtung, die eine Matrix umfasst, in der das Protein nach Anspruch 1, 2 oder 3 angeordnet ist.
17. Osteogene Vorrichtung zur Implantation in ein Säugetier, wobei die Vorrichtung Folgendes umfasst: (a) eine biokompatible, in vivo biologisch abbaubare Matrix, die ein Gerüst mit Abmessungen definiert, die ausreichend sind, um die Anlagerung, Proliferation und Differentiation von migratorischen Vorläuferzellen aus dem Körper des Säugetiers zu ermöglichen, und (b) das Protein nach Anspruch 1, 2 oder 3, das in der Matrix angeordnet und für diese Zellen zugänglich ist.
18. Vorrichtung nach Anspruch 16 oder Anspruch 17, wobei die Matrix eng gepacktes teilchenförmiges Material mit einer Teilchengröße im Bereich von 70 bis 850 µm (beispielsweise 70 bis 420 µm) umfasst.
19. Vorrichtung nach einem der Ansprüche 16 bis 18, wobei die Matrix Folgendes umfasst: (a) alloge-nen Knochen, beispielsweise demineralisierten, Protein-extrahierten, teilchenförmigen alloge-nen Knochen, (b) demineralisierten, Protein-extrahierten, teilchenförmigen, deglyk-sylierten xenogenen Knochen, (c) entmineralisierten, Protein-extrahierten, teilchenförmigen xenogenen Knochen, der mit HF oder einer Protease behandelt ist, (d) Materialien, die aus Kollagen, Hydroxyapatit, Calciumphosphaten (beispielsweise Tricalciumphosphat) und Polymeren ausgewählt sind, die Glycolsäure- und/oder Milchsäure-Monomere umfassen, (e) einen die Form behaltenden Feststoff aus locker haftendem teilchenförmigem Material, beispielsweise Kollagen, (f) einen porösen Feststoff oder (g) ein zerkleinertes Gewebe, beispielsweise Muskelge-webe.
20. Vorrichtung nach einem der Ansprüche 16 bis 19, die in der Markhöhle eines alloge-nen Knochens angeordnet ist.
21. Vorrichtung nach einem der Ansprüche 16 bis 20 zur Verwendung in der Therapie, beispielsweise zum Induzieren einer lokalen Knorpel- und/oder Ersatzknochen- oder heterotopen Knochenbildung in einem Säugetier durch Im-plantieren der Vorrichtung in ein Säugetier an einem Ort, der für migratorische Vorläuferzellen zugänglich ist.
22. Vorrichtung nach Anspruch 21 zur Bildung von geformten heterotopen Knochen, wobei die Form des heterotopen Knochens, der gebildet wird, derjenigen der implantierten Vorrichtung entspricht.
23. Verwendung des Proteins nach Anspruch 1, 2 oder 3 zur Herstellung des Folgenden: (a) einer Vorrichtung nach einem der Ansprüche 16 bis 21, oder (b) eines Medikamentes, wobei das Medikament oder die Vorrichtung zur Induktion einer lokalen Knorpel- und/oder Ersatzknochen- oder heterotopen Knochen-Bildung in einem Säugetier vorgesehen ist, indem das Medikament oder die Vorrichtung einem Säugetier an einem Ort eingebracht wird, der für migratorische Vorläuferzellen zugänglich ist, zur periodontalen Behandlung, Knorpelinsandsetzung und zur Behandlung der Osteoarthritis und zur Korrektur von nichtverheilenden Frakturen, erworbenen oder angeborenen kraniofazialen oder anderen Skelettoder dentalen Anomalien.
24. Verwendung nach Anspruch 23 zur Bildung eines geformten heterotopen Knochens, wobei die Form des hetero-topen Knochens, der gebildet wird, derjenigen der implantierten Vorrichtung entspricht.
25. Synthetisches Nukleinsäuremolekül zur Verwendung im Verfahren nach einem der Ansprüche 4 bis 8.
26. Wirtszelle zur Verwendung im Verfahren nach einem der Ansprüche 4 bis 8, die das synthetische Nukleinsäure-molekül nach Anspruch 25 enthält.
27. Wirtszelle nach Anspruch 26, die eine prokaryontische oder eukaryontische Wirtszelle ist, beispielsweise E. coli, Bacillus, Hefen oder Tierzellen (beispielsweise CHO oder Myeloma).
28. Isolierte DNA-Sequenz, die die Aminosäuresequenz des wie in einem der Ansprüche bis 3 oder 9 definierten Proteins kodiert.

Revendications

1. Protéine ostéogène comprenant une paire de chaînes polypeptidiques liées à l'état non réduit pour former une

espèce homodimère ou hétérodimère dont la conformation est telle que la paire de chaînes polypeptidiques est capable d'induire une ostéogenèse cartilagineuse lorsqu'elle est disposée à l'intérieur d'une matrice et implantée dans un mammifère, dans laquelle la protéine comprend une région contenant six résidus de cystéine disposés dans les positions relatives représentées dans la séquence :

LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXXQXXVX
XXNXXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX,

séquence dans laquelle les lettres indiquent les résidus d'acides aminés d'un code standard à lettre unique et chaque X représente n'importe quel acide aminé, avec cette réserve que l'on exclut le dpp:

2. Protéine selon la revendication 1, dans laquelle la protéine comprend une région contenant sept résidus de cystéine disposés dans les positions relatives représentées dans la séquence :

CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
QXXVXXNXXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX.

3. Protéine selon la revendication 1 ou 2, à savoir une protéine recombinante que l'on obtient par expression dans une cellule hôte.

4. Procédé pour produire une protéine ostéogène synthétique active, comme défini à la revendication 1, ladite protéine comprenant une paire de chaînes polypeptidiques liées via des ponts disulfure pour produire une espèce dimère, le procédé comprenant les étapes consistant à :

(a) produire une séquence consensus d'acides aminés en comparant des séquences d'acides aminés de protéines de la famille génique TGF-bêta, ladite séquence consensus conservant le modèle de réticulation via des ponts disulfure présent dans la séquence :

(i) LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXXQXXVXXNXXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX;

ou

(ii) CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXX
XXXXNHAXXQXXVXXNXXXXXPXXCCXPXXXXXXXXLXXXX
XXVXLXXYXXMXVXXCXCX;

séquence dans laquelle les lettres indiquent les résidus d'acides aminés d'un code standard à lettre unique et chaque X représente n'importe quel acide aminé ;

(b) construire un gène de synthèse encodant la séquence consensus d'acides aminés de l'étape (a) par exemple en assemblant deux oligonucléotides qui ont été synthétisés par voie chimique ;

(c) introduire le gène de synthèse obtenu par l'étape (b) dans une cellule hôte procaryote ou eucaryote ;

(d) exprimer le gène de synthèse pour produire une protéine ostéogène synthétique généralement admise ;

5 (e) analyser la protéine ostéogène synthétique généralement admise dans le but de déterminer le fait de savoir si elle est active en ce qui concerne l'induction d'une ostéogenèse cartilagineuse lors de son implantation dans un mammifère, et le cas échéant

10 (f) répéter les étapes (a) à (e) (ou procéder à une mutagenèse du gène de synthèse et répéter les étapes (c) à (e) lorsque la protéine ostéogène synthétique généralement admise se révèle inactive lors de l'analyse.

5. Procédé selon la revendication 4, dans lequel la séquence consensus d'acides nucléiques comprend la séquence :

15 (a) **LXVFXDXGWXXWXXXPXGXXAXYCXXCXXPXXXXXXXXN
HAXXQXXVXXNXXXPXXCCPXXXXXXXXLXXXXXXXXVXL
XXYXXMXVXXCXCX;**

20 ou

25 (b) **CXXXXLXVFXDXGWXXWXXXPXGXXAXYCXXCXXPXXXX
XXXXNHAXXQXXVXXNXXXPXXCCPXXXXXXXXLXXXX
XXVXLXXYXXMXVXXCXCX;**

30 séquence dans laquelle les lettres indiquent les résidus d'acides aminés d'un code standard à lettre unique et chaque X représente n'importe quel acide aminé.

35 6. Procédé selon l'une quelconque des revendications 4 à 5, dans lequel le gène de synthèse de l'étape (b) comprend une séquence nucléotidique qui encode une chaîne polypeptidique synthétique qui possède le même nombre de résidus de cystéine dans les mêmes positions relatives que COP5, COP7, COP16 ou OP1.

40 7. Procédé selon l'une quelconque des revendications 4 à 6, dans lequel le gène de synthèse de l'étape (b) comprend une séquence nucléotidique qui encode une chaîne polypeptidique synthétique qui partage un ou plusieurs acides aminés à des positions correspondantes dans l'une quelconque des séquences : Vg1, DPP, OP1, CBMP-2a, CBMP-2b, CBMP-3, COP1, COP3, COP4, COP5, COP7 ou COP16.

45 8. Procédé selon l'une quelconque des revendications 4 à 7, dans lequel le gène de synthèse de l'étape (b) comprend une séquence nucléotidique qui encode une chaîne polypeptidique synthétique comprenant la séquence d'acides aminés :

50

55

10 20 30 40 50
 CKRHPLYVDFRDVGWNDWIVPPGYHAFYCHGECPPFLADHLNSTNHAIV
 5 RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
 KE F E K I DN L N S Q ITK F P TL
 Q A S K
 60 70 80 90 100
 QTLVNSVNPGRIPKACCVPTLSAISMLYLDENENVVLKKNYQDMVVEGCGCR
 10 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S K DPV V Y N S H RN RS
 N S K P E

dans laquelle, dans chaque position dans laquelle on représente plus d'un acide aminé, l'un quelconque des acides
 aminés représentés peut se trouver dans cette position ; ou

10 20 30 40 50
 LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
 25 K S S L QE VIS E FD Y E A AY MPESMKAS VI
 F E K I DN L N S Q ITK F P TL
 A S K
 60 70 80 90 100
 QTLVNSVNPGRIPKACCVPTLSAISMLYLDENENVVLKKNYQDMVVEGCGCR
 30 SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
 RF T S X DPV V Y N S H RN RS
 N S K P E

dans laquelle, dans chaque position dans laquelle on représente plus d'un acide aminé, l'un quelconque des acides
 aminés représentés peut se trouver dans cette position ; ou

(c)
 1 10 20 30 40
 CRRHSLYVDFS-DVGWDDWIVAPLGIDAYYCHGKCPFLAD
 45 50 60 70
 HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
 80 90 100
 50 VAMLYLNDQSTVVLKKNYQDMVVEGCGCR;

ou

10

ou

-5

20

25

out

35

40

OU

55

(g)

1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPGR-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENERKVVLKQYQEMVVEGCGCR;

ou

(h)

1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPGR-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENERKVVLKKYQEMVVEGCGCR.

9. Protéine selon l'une quelconque des revendications 1 à 3, dans laquelle la protéine comprend une chaîne polypeptidique synthétique contenant moins de 200 acides aminés.
10. Protéine selon l'une quelconque des revendications 4 à 8, dans laquelle la protéine comprend une chaîne polypeptidique synthétique contenant moins de 200 acides aminés.
11. Protéine selon la revendication 3, dans laquelle la cellule hôte est une cellule hôte procaryote ou eucaryote, par exemple des cellules de E. coli, de Bacillus, de levure ou des cellules animales (par exemple des cellules CHO ou des cellules de myélome).
12. Procédé selon l'une quelconque des revendications 4 à 8 ou 10 dans lequel la cellule hôte est une cellule hôte procaryote ou eucaryote par exemple des cellules de E. coli, de Bacillus, de levure ou des cellules animales (par exemple des cellules CHO ou des cellules de myélome).
13. Protéine selon l'une quelconque des revendications 1 à 3, dans laquelle la protéine est non glycosylée.
14. Procédé selon l'une quelconque des revendications 4 à 8 ou 10 dans lequel la protéine est non glycosylée.
15. Composition comprenant une protéine comprenant une paire de chaînes polypeptidiques liées via des ponts disulfure pour produire une espèce dimère, la protéine étant telle que définie à la revendication 1, 2 ou 3.
16. Dispositif ostéogène comprenant une matrice dans laquelle est disposée la protéine selon la revendication 1, 2 ou 3.
17. Dispositif ostéogène à des fins d'implantation dans un mammifère, le dispositif comprenant : (a) une matrice biocompatible, biodégradable in vivo définissant un support de dimension suffisante pour permettre la fixation, la

prolifération et la différenciation de cellules souches migratrices à partir du corps dudit mammifère, et (b) la protéine selon la revendication 1, 2 ou 3 disposée dans ladite matrice et accessible auxdites cellules.

- 5 18. Dispositif selon la revendication 16 ou 17, dans lequel ladite matrice comprend une matière particulaire fortement densifiée qui possède une granulométrie dans la plage de 70 à 850 µm (par exemple de 70 à 420 µm).
- 10 19. Dispositif selon l'une quelconque des revendications 16 à 18, dans lequel ladite matrice comprend : (a) de l'os allogène, par exemple de l'os allogène, particulaire, extrait d'une protéine, déminéralisé ; (b) de l'os xénogène déglycosylé, particulaire, extrait d'une protéine, déminéralisé ; (c) de l'os xénogène déglycosylé, particulaire, extrait d'une protéine, déminéralisé, qui a été traité avec du HF ou avec une protéase ; (d) de matière choisie parmi le groupe comprenant le collagène, l'hydroxy-apatite, des phosphates de calcium (par exemple le phosphate trical-
15 cique) et des polymères comprenant des monomères d'acide glycolique et/ou d'acide lactique ; (e) un produit solide conservant sa forme, constituée d'une matière particulaire présentant une adhérence lâche, par exemple du collagène ; (f) un produit solide poreux ; ou (g) un tissu masticateur, par exemple un muscle.
- 20 20. Dispositif selon l'une quelconque des revendications 16 à 19, placé dans la cavité médullaire d'os allogène.
21. Dispositif selon l'une quelconque des revendications 16 à 20, à utiliser en thérapie, par exemple pour induire une formation locale de cartilage et/ou d'os enchondral ou hétérotope chez un mammifère par implantation du dispositif dans un mammifère à un site accessible à des cellules souches migratrices.
- 25 22. Dispositif selon la revendication 21, pour la formation d'os hétérotope configuré, dans lequel la configuration de l'os hétérotope à l'état formé épouse celle du dispositif implanté.
- 30 23. Utilisation de la protéine selon la revendication 1, 2 ou 3 pour la fabrication : (a) d'un dispositif selon l'une quel-
conque des revendications 16 à 21 ou (b) d'un médicament, le médicament ou le dispositif étant destiné à induire une formation locale de cartilage et/ou d'os enchondral ou hétérotope chez un mammifère en introduisant le mé-
dicament ou le dispositif dans un mammifère à un site accessible à des cellules souches migratrices pour un traitement parodontal, une réparation de cartilage et pour le traitement de l'arthrose ou encore pour corriger des fractures en l'absence de soudure, des anomalies craniofaciales acquises ou congénitales, et d'autres anomalies squelettiques ou dentaires.
- 35 24. Utilisation selon la revendication 23 pour la formation d'os hétérotope configuré, dans lequel la configuration de l'os hétérotope à l'état formé épouse celle du dispositif implanté.
25. Molécule synthétique d'acide nucléique à utiliser dans le procédé selon l'une quelconque des revendications 4 à 8.
- 40 26. Cellule hôte à utiliser dans le procédé selon l'une quelconque des revendications 4 à 8, qui contient la molécule synthétique d'acide nucléique de la revendication 25.
27. Cellule hôte selon la revendication 26, à savoir une cellule hôte procaryote ou eucaryote, par exemple des cellules de E. coli, de Bacillus, de levure ou des cellules animales (par exemple des cellules CHO ou des cellules de myélome).
- 45 28. Séquence d'ADN isolée qui encode la séquence d'acides aminés de la protéine telle que définie dans l'une quel-
conque des revendications 1 - 3 ou 9.

50

55

[illegible]

FIG. 1-2

Y,f,n	Y,f,n	C	e,h,*	g	e,a*	C	p,a,g,q	f,Y	p	l,m,i	p,a,s,t	d,e,s,g*	h,r,n,s*	m,l,f,p,sa	n,k	s,a,p,g	t,s,a	n	h	a,t,s	i,v,t	v,i,l	q,n	t,s,a,g	l,i	v	h,n,r			
:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
H	Y	C	H	G	G	C	G	L	H	I	P	P	N	L	S	L	P	V	P	G	A	P	P	T	P	A	Q	P	Y	
N	N	C	Q	G	V	C	G	W	P	Q	S	D	R	N	P	R	Y	G	N	H	V	V	L	L	L	K	M			
:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
N	F	C	L	G	P	A	C	P	Y	I	W	S	L	S	A	T	Q	Q	Y	H	S	K	R	V	L	A	L	Y	N	
N	Y	C	E	G	S	C	P	A	Y	L	A	G	V	P	G	S	A	S	S	F	H	T	A	V	V	N	Q	Y	R	M
N	Y	C	E	G	E	C	P	S	H	I	A	G	T	S	G	S	S	L	S	F	H	S	T	V	I	N	H	Y	R	M
Y	Y	C	S	G	A	C	Q	F	P	M	P	K	S	L	K	P	S	N	H	A	T	I	Q	S	I	V	R			
:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:		
F	Y	C	H	G	E	C	P	F	P	L	A	D	H	L	N	S	T	N	H	A	I	V	Q	T	L	V	N			
Y	Y	C	E	G	E	C	A	F	P	L	N	S	Y	M	N	A	T	N	H	A	I	V	Q	T	L	V	H			
Y	Y	C	H	G	K	C	P	F	P	L	A	D	H	F	N	S	T	N	H	A	V	V	Q	T	L	V	N			
N	Y	C	Y	G	E	C	P	Y	P	L	T	E	I	L	N	G	S	N	H	A	I	L	Q	T	L	V	H			
:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
F	Y	C	H	G	E	C	P	F	P	L	A	D	H	L	N	S	T	N	H	A	V	V	Q	T	L	V	N			
F	Y	C	S	G	A	C	Q	F	P	S	A	D	H	F	N	S	T	N	H	A	V	V	Q	T	L	V	N			
Y	Y	C	S	G	A	C	Q	F	P	S	A	D	H	F	N	S	T	N	H	A	V	V	Q	T	L	V	N			

FIG. 1-3

n,s*	i,v,l,	n	p,s,a	g,e	k,q,t,s	i,v,l	p,a,s	k	a,p,s	c	c	v,a,i	p,s,a	t,e,q	q,e,d,k*	l,m	s,n,e,d	a,s,p,t	i,l,m,v	s,a,p,t	v,m,i,l	l,v,i	y,f	f,l,y	d,n	d,e	n,q,y*	e,d,s,t			
S	L	L	P	G	A	Q	P	C	C	A	A	L	P	G	T	M	R	P	L	H	V	R	T	T	S	D					
Q	A	R	G	A	A	L	A	R	P	P	C	C	V	P	T	A	Y	A	G	K	L	L	I	S	L	S	E	E	R		
T	T	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
Q	T	I	L	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
Q	H	N	P	G	A	S	A	S	A	P	C	C	C	V	P	Q	A	L	E	P	L	P	I	V	Y	Y	V	G	R	K	T
R	G	L	N	P	G	T	K	V	N	S	C	C	C	I	P	T	K	L	S	T	M	S	M	L	Y	F	D	D	E	Y	
R	G	H	S	P	F	A	N	L	K	S	C	C	C	V	P	T	K	L	R	P	M	S	M	L	Y	Y	D	D	G	Q	
A	V	G	V	V	P	G	I	P	E	P	C	C	C	V	P	E	K	M	S	S	S	L	S	I	L	F	F	D	E	N	K
:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:		
S	V	N	S	K	I	P	K	A	C	C	V	P	T	E	L	S	A	I	S	M	L	Y	L	D	E	N	E	Y	D		
F	I	N	P	E	T	V	P	K	A	C	C	A	P	T	Q	L	N	A	I	S	V	L	Y	F	D	D	S	S			
N	N	N	P	G	K	V	P	K	A	C	C	V	P	T	Q	L	D	S	V	A	M	L	Y	L	N	D	Q	S			
S	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
S	S	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
S	S	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:	:			
N	N	M	N	P	G	K	V	P	K	P	C	C	V	P	T	E	L	S	A	I	S	M	L	Y	L	D	E	N	E		
N	N	M	N	P	G	K	V	P	K	P	C	C	V	P	T	E	L	S	A	I	S	M	L	Y	L	D	E	N	E		
N	N	M	N	P	G	K	V	P	K	P	C	C	V	P	T	E	L	S	A	I	S	M	L	Y	L	D	E	N	E		

FIG. 1-4

[illegible]




FIG. 2A

FIG. 2B-1

COP-5 fusion protein

```

      10      20      30      40      50
ATGAAAGCAATTTTCGTACTGAAAGGTTCACTGGACAGAGATCTGGACTC
M  K  A  I  F  V  L  K  G  S  L  D  R  D  L  D  S
                               BglIII

      60      70      80      90     100
TCGTCTGGATCTGGACGTTTCGTACCGACCACAAAGACCTGTCTGATCACC
R  L  D  L  D  V  R  T  D  H  K  D  L  S  D  H

     110     120     130     140     150
TGGTTCTGGTTCGACCTGGCTCGTAACGACCTGGCTCGTATCGTTACTCCC
L  V  L  V  D  L  A  R  N  D  L  A  R  I  V  T  P
      SalI                               Sma

     160     170     180     190     200
GGGTCTCGTTACGTTGCGGATCTGGAATTCATGGCTGACAACAAATTCAA
G  S  R  Y  V  A  D  L  E  F  M  A  D  N  K  F  N
I                               EcoRI

     210     220     230     240     250
CAAGGAACAGCAGAACGCGTTCTACGAGATCTTGCCACCTGCCGAACCTGA
K  E  Q  Q  N  A  F  Y  E  I  L  H  L  P  N  L
              MluI          BglIII      BspMI+

     260     270     280     290     300
ACGAAGAGCAGCGTAACGGCTTCATCCAAAGCTTGAAGGATGAGCCCTCT
N  E  E  Q  R  N  G  F  I  Q  S  L  K  D  E  P  S
                               HindIII

     310     320     330     340     350
CAGTCTGCCGAATCTGCTAGCGGATGCCAAGAACTGAACGATGCGCAGGC
Q  S  A  N  L  L  A  D  A  K  K  L  N  D  A  Q  A
              NheI                               FspI

     360     370     380     390     400
ACCGAAATCGGATCAGGGGCAATTCATGGCTGACAACAAATTCAACAAGG
P  K  S  D  Q  G  Q  F  M  A  D  N  K  F  N  K

     410     420     430     440     450
AACAGCAGAACGCGTTCTACGAGATCTTGCCACCTGCCGAACCTGAACGAA
E  Q  Q  N  A  F  Y  E  I  L  H  L  P  N  L  N  E
      MluI          BglIII      BspMI+

     460     470     480     490     500
GAGCAGCGTAACGGCTTCATCCAAAGCTTGAAGGATGAGCCCTCTCAGTC
E  Q  R  N  G  F  I  Q  S  L  K  D  E  P  S  Q  S
                               HindIII

```

FIG. 2B-2

510 520 530 540 550
 TCGGAATCTGCTAGCGGATGCCAAGAACTGAACGATGCGCAGGCACCGA
 A N L L A D A K K L N D A Q A P
 NheI FspI

560 570 580 590 600
 AGGATCCTAATGGGCTGTACGTCGACTTCAGCGACGTGGGCTGGGACGAC
 K D P N G L Y V D F S D V G W D D
 BamHI Sali

610 620 630 640 650
 TGGATTGTGGCCCCACCAGGCTACCAGGCCTTCTACTGCCATGGCGAATG
 W I V A P P G Y Q A F Y C H G E C
 StuI NcoI BsmI+

660 670 680 690 700
 CCCTTTCCCGCTAGCGGATCACTTCAACAGCACCAACCACGCCGTGGTGC
 P F P L A D H F N S T N H A V V
 NheI DraIII
 PflMI

710 720 730 740 750
 AGACCCTGGTGAACCTCTGTCAACTCCAAGATCCCTAAGGCTTGCTGCGTG
 Q T L V N S V N S K I P K A C C V
 MstII

760 770 780 790 800
 CCCACCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATGAGAA
 P T E L S A I S M L Y L D E N E K
 SphI

810 820 830 840 850
 GGTGGTGCTGAAGAACTACCAGGAGATGGTAGTAGAGGGCTGCGGCTGCC
 V V L K N Y Q E M V V E G C G C
 PflMI

860
 GCTAACTGCAG
 R *
 PstI

FIG. 3A




FIG. 3B



FIG. 4

10 20 30 40 50
GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACGA
D P N G L Y V D F Q R D V G W D D

60 70 80 90 100
CTGGATCATCGCCCCCGTCGACTTCGACGCCTACTACTGCTCCGGAGCCT
W I I A P V D F D A Y Y C S G A

110 120 130 140 150
GCCAGTTCCCCTCTGCGGATCACTTCAACAGCACCAACCACGCCGTGGTG
C Q F P S A D H F N S T N H A V V

160 170 180 190 200
CAGACCCTGGTGAACAACATGAACCCCGGCAAGGTACCCAAGCCCTGCTG
Q T L V N N M N P G K V P K P C C

210 220 230 240 250
CGTGCCCAACGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATT
V P T E L S A I S M L Y L D E N

260 270 280 290 300
CCACCGTGGTGCTGAAGAACTACCAGGAGATGACCGTGGTGGGCTGCGGC
S T V V L K N Y Q E M T V V G C G

310
TGCCGCTAACTGCAG
C R *